First Time Loading...

Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 745.95 USD -0.64% Market Closed
Updated: Apr 19, 2024

Intrinsic Value

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. [ Read More ]

The intrinsic value of one LLY stock under the Base Case scenario is 342.38 USD. Compared to the current market price of 745.95 USD, Eli Lilly and Co is Overvalued by 54%.

Key Points:
LLY Intrinsic Value
Base Case
342.38 USD
Overvaluation 54%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Eli Lilly and Co

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling LLY stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Eli Lilly and Co

Provide an overview of the primary business activities
of Eli Lilly and Co.

What unique competitive advantages
does Eli Lilly and Co hold over its rivals?

What risks and challenges
does Eli Lilly and Co face in the near future?

Has there been any significant insider trading activity
in Eli Lilly and Co recently?

Summarize the latest earnings call
of Eli Lilly and Co.

What significant events have occurred
in Eli Lilly and Co over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Eli Lilly and Co.

Provide P/S
for Eli Lilly and Co.

Provide P/E
for Eli Lilly and Co.

Provide P/OCF
for Eli Lilly and Co.

Provide P/FCFE
for Eli Lilly and Co.

Provide P/B
for Eli Lilly and Co.

Provide EV/S
for Eli Lilly and Co.

Provide EV/GP
for Eli Lilly and Co.

Provide EV/EBITDA
for Eli Lilly and Co.

Provide EV/EBIT
for Eli Lilly and Co.

Provide EV/OCF
for Eli Lilly and Co.

Provide EV/FCFF
for Eli Lilly and Co.

Provide EV/IC
for Eli Lilly and Co.

Show me price targets
for Eli Lilly and Co made by professional analysts.

What are the Revenue projections
for Eli Lilly and Co?

How accurate were the past Revenue estimates
for Eli Lilly and Co?

What are the Net Income projections
for Eli Lilly and Co?

How accurate were the past Net Income estimates
for Eli Lilly and Co?

What are the EPS projections
for Eli Lilly and Co?

How accurate were the past EPS estimates
for Eli Lilly and Co?

What are the EBIT projections
for Eli Lilly and Co?

How accurate were the past EBIT estimates
for Eli Lilly and Co?

Compare the revenue forecasts
for Eli Lilly and Co with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Eli Lilly and Co and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Eli Lilly and Co against its competitors.

Analyze the profit margins
(gross, operating, and net) of Eli Lilly and Co compared to its peers.

Compare the P/E ratios
of Eli Lilly and Co against its peers.

Discuss the investment returns and shareholder value creation
comparing Eli Lilly and Co with its peers.

Analyze the financial leverage
of Eli Lilly and Co compared to its main competitors.

Show all profitability ratios
for Eli Lilly and Co.

Provide ROE
for Eli Lilly and Co.

Provide ROA
for Eli Lilly and Co.

Provide ROIC
for Eli Lilly and Co.

Provide ROCE
for Eli Lilly and Co.

Provide Gross Margin
for Eli Lilly and Co.

Provide Operating Margin
for Eli Lilly and Co.

Provide Net Margin
for Eli Lilly and Co.

Provide FCF Margin
for Eli Lilly and Co.

Show all solvency ratios
for Eli Lilly and Co.

Provide D/E Ratio
for Eli Lilly and Co.

Provide D/A Ratio
for Eli Lilly and Co.

Provide Interest Coverage Ratio
for Eli Lilly and Co.

Provide Altman Z-Score Ratio
for Eli Lilly and Co.

Provide Quick Ratio
for Eli Lilly and Co.

Provide Current Ratio
for Eli Lilly and Co.

Provide Cash Ratio
for Eli Lilly and Co.

What is the historical Revenue growth
over the last 5 years for Eli Lilly and Co?

What is the historical Net Income growth
over the last 5 years for Eli Lilly and Co?

What is the current Free Cash Flow
of Eli Lilly and Co?

Financials

Balance Sheet Decomposition
Eli Lilly and Co

Current Assets 25.7B
Cash & Short-Term Investments 2.9B
Receivables 11.3B
Other Current Assets 11.5B
Non-Current Assets 38.3B
Long-Term Investments 3.1B
PP&E 12.9B
Intangibles 11.8B
Other Non-Current Assets 10.5B
Current Liabilities 27.3B
Accounts Payable 2.6B
Accrued Liabilities 13.3B
Other Current Liabilities 11.4B
Non-Current Liabilities 25.9B
Long-Term Debt 18.3B
Other Non-Current Liabilities 7.6B
Efficiency

Earnings Waterfall
Eli Lilly and Co

Revenue
34.1B USD
Cost of Revenue
-7.1B USD
Gross Profit
27B USD
Operating Expenses
-16.7B USD
Operating Income
10.3B USD
Other Expenses
-5.1B USD
Net Income
5.2B USD

Free Cash Flow Analysis
Eli Lilly and Co

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

LLY Profitability Score
Profitability Due Diligence

Eli Lilly and Co's profitability score is 71/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
Exceptional ROE
Negative Free Cash Flow
71/100
Profitability
Score

Eli Lilly and Co's profitability score is 71/100. The higher the profitability score, the more profitable the company is.

LLY Solvency Score
Solvency Due Diligence

Eli Lilly and Co's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Long-Term Solvency
Short-Term Solvency
65/100
Solvency
Score

Eli Lilly and Co's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LLY Price Targets Summary
Eli Lilly and Co

Wall Street analysts forecast LLY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LLY is 843.06 USD with a low forecast of 545.4 USD and a high forecast of 1 050 USD.

Lowest
Price Target
545.4 USD
27% Downside
Average
Price Target
843.06 USD
13% Upside
Highest
Price Target
1 050 USD
41% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

LLY Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

LLY Price
Eli Lilly and Co

1M 1M
-3%
6M 6M
+26%
1Y 1Y
+102%
3Y 3Y
+305%
5Y 5Y
+594%
10Y 10Y
+1 402%
Annual Price Range
745.95
52w Low
369.51
52w High
792.28
Price Metrics
Average Annual Return 36.74%
Standard Deviation of Annual Returns 21.52%
Max Drawdown -10%
Shares Statistics
Market Capitalization 708.2B USD
Shares Outstanding 950 770 000
Percentage of Shares Shorted 0.64%

LLY Return Decomposition
Main factors of price return

What is price return decomposition?

LLY News

Other Videos

Last Important Events
Eli Lilly and Co

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Eli Lilly and Co

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Eli Lilly and Co Logo
Eli Lilly and Co

Country

United States of America

Industry

Pharmaceuticals

Market Cap

708.2B USD

Dividend Yield

0.69%

Description

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 35,000 full-time employees. The firm is engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products across the world. The firm's diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta and Trulicity. Its oncology products include Alimta, Cyramza, Erbitux, Retevmo, Tyvyt and Verzenio. The firm's immunology products consist of Olumiant and Taltz. Its neuroscience products include Cymbalta, Emgality, Reyvow and Zyprexa. Its other therapies consist of Bamlanivimab, etesevimab, Cialis and Forteo. The firm manufactures and distributes its products through facilities in the United States, including Puerto Rico, and about eight other countries. Its products are sold in approximately 120 countries. Its subsidiaries include Acanthas Pharma, Inc., Alnara Pharmaceuticals, Inc., ARMO Biosciences, Inc., and Avid Radiopharmaceuticals, Inc., among others.

Contact

INDIANA
Indianapolis
Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr
+13172762000.0
https://www.lilly.com/

IPO

1970-07-09

Employees

35 000

Officers

Chairman, CEO & President
Mr. David A. Ricks
Executive VP & CFO
Ms. Anat Ashkenazi
EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology
Dr. Daniel M. Skovronsky M.D., Ph.D.
Executive VP, General Counsel & Secretary
Ms. Anat Hakim J.D.
Executive VP & President of Loxo
Mr. Jacob S. Van Naarden
Senior VP of Finance & Chief Accounting Officer
Mr. Donald A. Zakrowski
Show More
EVP & Chief Information and Digital Officer
Mr. Diogo Rau
EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer
Mr. Alonzo Weems
Executive Vice President of Human Resources & Diversity
Mr. Eric Dozier
Senior VP & President of Elanco Animal Health
Mr. Jeffrey N. Simmons
Show Less

See Also

Discover More
What is the Intrinsic Value of one LLY stock?

The intrinsic value of one LLY stock under the Base Case scenario is 342.38 USD.

Is LLY stock undervalued or overvalued?

Compared to the current market price of 745.95 USD, Eli Lilly and Co is Overvalued by 54%.